5 Minute News

New lung cancer therapies received positive opinion from EMA

November 17, 2026

Two new therapies for lung cancer have received positive opinions from the European Medicines Agency (EMA). The drugs Aumseqa and Zybrivo are intended for specific groups of patients with non-small cell lung cancer. In contrast, the ivonescimab treatment was not approved by the U.S. FDA as it failed to show a statistically significant improvement in overall survival. The positive opinions from the EMA still require approval from the European Commission for market release. The rapid development of new therapies highlights progress in cancer treatment.